Authorship：Lead author   Language：Japanese   Publishing type：Research paper (scientific journal)  

DOI： 10.1177/0271678X20972656

Web of Science

PubMed

Authorship：Lead author   Language：English   Publishing type：Doctoral thesis  

DOI： 10.1016/j.jcyt.2020.01.009

PubMed

Language：English   Publishing type：Research paper (scientific journal)   Publisher：Neonatology  

Introduction: The effects of hydrocortisone (HDC) administration to extremely low birth weight (ELBW) infants on later development remain unclear. This study examined the association between HDC dosage during neonatal period and neurodevelopmental outcomes in ELBW infants. Methods: This study was a retrospective cohort study conducted in eight centers in Japan. The subjects of this study were ELBW infants born between April 2015 and March 2017. The association between postnatal total HDC dosage up to 36 weeks postmenstrual age and the developmental quotient (DQ) at 3 years of age was examined. Multiple linear regression evaluated the association, adjusting for weeks of gestation, birth weight, and the presence of bronchopulmonary dysplasia, late-onset circulatory collapse, intracranial hemorrhage, necrotizing enterocolitis, and sepsis. Results: This study included 218 ELBW infants, of whom 144 underwent a developmental test at 3 years of age. Simple linear regression analysis revealed a significant association between total HDC dosage and DQ at 3 years of age (coefficients: -2.65, 95% CI: -3.73, -1.57). Multiple linear regression analysis adjusted for the presence of bronchopulmonary dysplasia and late-onset circulatory collapse also revealed a significant association between total HDC dosage and DQ at 3 years of age (coefficients: -2.66, 95% CI: -3.89, -1.42). Conclusion: Higher total HDC dosage up to 36 weeks postmenstrual age in ELBW infants was associated with impaired neurodevelopmental outcomes. Although HDC is often needed in the treatment of ELBW infants, clinicians should be aware that an increased dose of HDC may be associated with impaired neurodevelopmental outcomes.

DOI： 10.1159/000534934

Scopus

PubMed

Language：English   Publisher：Scientific Reports  

Multilineage-differentiating stress-enduring (Muse) cells are endogenous reparative pluripotent stem cells present in the bone marrow, peripheral blood, and organ connective tissues. We assessed the homing and therapeutic effects of systemically administered nafimestrocel, a clinical-grade human Muse cell-based product, without immunosuppressants in a neonatal hypoxic–ischemic (HI) rat model. HI injury was induced on postnatal day 7 (P7) and was confirmed by T2-weighted magnetic resonance imaging on P10. HI rats received a single dose nafimestrocel (1 × 106 cells/body) or Hank’s balanced salt solution (vehicle group) intravenously at either three days (on P10; M3 group) or seven days (on P14; M7 group) after HI insult. Radioisotope experiment demonstrated the homing of chromium-51-labeled nafimestrocel to the both cerebral hemispheres. The cylinder test (M3 and M7 groups) and open-field test (M7 group) showed significant amelioration of paralysis and hyperactivity at five weeks of age compared with those in the vehicle group. Nafimestrocel did not cause adverse events such as death or pathological changes in the lung at ten weeks in the both groups. Nafimestrocel attenuated the production of tumor necrosis factor-α and inducible nitric oxide synthase from activated cultured microglia in vitro. These results demonstrate the potential therapeutic benefits and safety of nafimestrocel.

DOI： 10.1038/s41598-023-41026-3

Scopus

PubMed

Language：English   Publisher：Pediatrics International  

DOI： 10.1111/ped.15698

Scopus

PubMed

Language：Japanese   Publishing type：Article, review, commentary, editorial, etc. (trade magazine, newspaper, online media)  

Authorship：Lead author   Language：Japanese   Publishing type：Article, review, commentary, editorial, etc. (trade magazine, newspaper, online media)  

Authorship：Lead author   Language：Japanese   Publishing type：Article, review, commentary, editorial, etc. (trade magazine, newspaper, online media)  

Authorship：Lead author   Language：Japanese   Publishing type：Article, review, commentary, editorial, etc. (trade magazine, newspaper, online media)  

Event date： 2022.3

Language：English   Presentation type：Oral presentation (general)  

Country：Taiwan, Province of China  

Event date： 2018.5

Language：English   Presentation type：Poster presentation  

Country：Canada  

Event date： 2023.11

Language：Japanese   Presentation type：Public lecture, seminar, tutorial, course, or other speech  

Event date： 2022.11

Language：Japanese   Presentation type：Public lecture, seminar, tutorial, course, or other speech  

Venue：パシフィコ横浜  

Event date： 2017.10

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：埼玉   Country：Japan  

Applicant：佐藤義朗、鈴木俊彦、清水忍、水野正明、早川昌弘、出澤真理

Application no：2016-098186  Date applied：2016.5

Country of applicant：Domestic  

Multilineage-differentiating Stress Enduring（Muse）細胞は、多能性を有し直接的に分化転換・組織修復を行うことができる間葉系幹細胞の数％を構成する細胞である。我々はHIEモデル動物で、Muse細胞が脳へ生着すること、並びに行動学的に学習及び運動障害の改善効果があることを確認した。現在HIEの治療法は、効果が限定的な低体温療法しかなく、新規治療法の開発が喫緊の課題とされている。本研究でMuse細胞を用いたHIEの新規治療法の開発を行うことにより、神経学的予後を改善する効果が期待できる。

下痢、血便、乏尿、顔色不良を題材としたPBLチュートリアルのまとめ・総括を実施した。

発熱を題材としたPBLチュートリアルに関して、まとめ・総括を実施した。